Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PADCEV vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
FDA-approved: Treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.,Off-label: None established.
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Approximately 3.4 days (range 2.8-4.2 days) at steady state, supporting every-3-week dosing. Terminal half-life consistent with Ig G1 clearance.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
The small molecule MMAE is metabolized primarily by CYP3A4. Enfortumab, the antibody component, is catabolized to small peptides and amino acids.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily metabolized via catabolism into small peptides and amino acids; minimal renal excretion (<5% unchanged drug in urine). No biliary/fecal data available.
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
No specific protein binding data; as a monoclonal antibody, it is not highly bound to plasma proteins (expected <10%).
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Approximately 0.07 L/kg (7.0 L in 70 kg patient), indicating limited extravascular distribution and consistent with distribution into vascular and interstitial spaces.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Administered intravenously only; bioavailability 100% by IV route.
Intravenous administration yields 100% bioavailability.
No dose adjustment recommended for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73m2). Use not recommended in severe renal impairment (e GFR <30 m L/min/1.73m2) or ESRD.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
No formal studies; mild (Child-Pugh A) and moderate (Child-Pugh B) may use with caution; not recommended in severe (Child-Pugh C).
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and effectiveness in pediatric patients have not been established.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment recommended based on age alone; monitor closely for adverse effects due to potential comorbidities and polypharmacy.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
WARNING: SERIOUS SKIN REACTIONS. PADCEV can cause severe, life-threatening or fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Discontinue PADCEV immediately if signs or symptoms of SJS or TEN occur and permanently discontinue if confirmed.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Cutaneous adverse reactions: Monitor for severe skin reactions; interrupt or discontinue as appropriate.,Hyperglycemia: Monitor blood glucose levels, especially in patients with diabetes or risk factors; manage with antihyperglycemics.,Ocular disorders: May cause keratitis, dry eye, or blurred vision; monitor and refer to ophthalmologist.,Peripheral neuropathy: Monitor for new or worsening neuropathy; dose adjustment may be required.,Pneumonitis or interstitial lung disease: Monitor for signs and symptoms; discontinue if confirmed.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
None.
None known.
No specific food interactions reported. However, patients should maintain adequate hydration. Avoid grapefruit and grapefruit juice if taking concurrent CYP3A4 substrates.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
PADCEV (enfortumab vedotin) is a pregnancy category D drug. Based on its mechanism of action (MMAE-mediated disruption of microtubules), there is a potential risk of fetal harm. Advise pregnant women of the potential risk to the fetus. First trimester: Highest risk of major congenital malformations. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to MMAE's anti-mitotic effects.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
No data on presence of enfortumab vedotin or its metabolites in human milk. M/P ratio unknown. Because many drugs are excreted in human milk and due to potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for at least 3 weeks after the last dose.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. The drug should be avoided during pregnancy unless the benefit outweighs risks. Physiologic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure, but no dose adjustment guidelines exist.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
PADCEV (enfortumab vedotin-ejfv) is a Nectin-4-directed antibody-drug conjugate used in locally advanced or metastatic urothelial carcinoma. Monitor for peripheral neuropathy, skin reactions, and hyperglycemia. Premedicate with antihistamines and antipyretics to reduce infusion reactions. Dose reductions may be needed for Grade 3 or higher adverse events.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
Report any new or worsening numbness, tingling, or pain in hands or feet immediately.,Monitor for signs of skin reactions such as rash, itching, or blisters, and avoid sun exposure.,Check blood glucose regularly if you have diabetes or are at risk for hyperglycemia.,Use effective contraception during treatment and for at least 2 weeks after the last dose.,Avoid live vaccines during treatment.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PADCEV vs COLUMVI, answered by our medical review team.
PADCEV is a Antineoplastic Agent that works by Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PADCEV and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PADCEV is: 1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PADCEV and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PADCEV is classified as Category C. PADCEV (enfortumab vedotin) is a pregnancy category D drug. Based on its mechanism of action (MMAE-mediated disruption of microtubules), there is a potential risk of fetal harm. Ad. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.